Lantheus price target raised to $99 from $95 at B. Riley

B. Riley raised the firm’s price target on Lantheus to $99 from $95 and keeps a Buy rating on the shares. The analyst is increasingly positive on Pylarify’s growth in Q1 following Telix’s Q1 earnings report. The favorable trend of Telix’s Illuccix read positively to Pylarify, the analyst tells investors in a research note. The firm continues to view Lantheus as “best fitted for revenue-falling big pharma to acquire and take a leadership position in this emergent radiopharma space.”